- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05908682
Sikkerhet for gravide personer utsatt for Ibrexafungerp, inkludert spedbarnsutfall
En enkeltarms sikkerhetsstudie av forsøkspersoner eksponert for Ibrexafungerp mens de er gravide, inkludert spedbarnsutfall opptil ett år
This is an ongoing evaluation of subjects exposed to ibrexafungerp while pregnant. The study population will include pregnant women of any age.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
This is a single-arm safety study which comprises an ongoing evaluation of subjects exposed to ibrexafungerp while pregnant. The study population will include pregnant women of any age who were exposed to ibrexafungerp during pregnancy, or whose conception is estimated to have occurred within four days after receiving last dose of ibrexafungerp, and are volunteering to take part in this study. Subjects will be monitored starting from exposure during pregnancy until one year after live delivery.
Information on pregnancy outcomes and complications as well as fetal/neonatal/infant outcomes will be collected during the timeframe described in the protocol.
Subjects can enroll in the study by calling the telephone number directly (1-888-982-7299) or through SCYNEXIS BREXAFEMME Pregnancy Study Webpage, OR her healthcare provider (HCP) can, with her consent, enroll her on her behalf.
Data will be collected both retrospectively and prospectively using a variety of questionnaire that will be completed by the representative based on interview with the subject and/or HCP
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Sanjeev Miglani, MD
- Telefonnummer: +91-9910533655
- E-post: sanjeev.miglani@awinsals.com
Studiesteder
-
-
Vasant Vihar
-
New Delhi, Vasant Vihar, India, 110057
- Rekruttering
- AWINSA
-
Ta kontakt med:
- Sanjeev Miglani, MD
- Telefonnummer: +91-9910533655
- E-post: sanjeev.miglani@awinsals.com
-
Hovedetterforsker:
- Sanjeev Miglani, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
The study population will include women who were exposed to ibrexafungerp at any time during pregnancy or whose conception is estimated to have occurred within four days after receiving last dose of ibrexafungerp, volunteering to take part in this study.
Beskrivelse
Inclusion Criteria:
-
Exposure to ibrexafungerp during pregnancy or if conception is estimated to have occurred within 4 days of the last dose of ibrexafungerp
-
Subject and/or parent/legal representative consents to participate and agrees to the conditions and requirements of the study including the interview schedule/completion of questionnaire and release of medical records
- Subject can be identified by the sponsor or HCP, in terms of confirmed pregnancy.
A self-reported pregnancy will be considered as confirmed pregnancy if the Urine Pregnancy Test (UPT) result is positive.
- A woman can self-enroll in the study or her healthcare provider (HCP), with her consent, can enroll her on her behalf.
Exclusion Criteria:
- Females who were not exposed to safety study medications during pregnancy
- Refusal to participate in the study
- An inability to provide an accurate medical history or give informed consent
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: CASE_ONLY
- Tidsperspektiver: OTHER
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Study Cohort
Subjects who have been treated with Brexafemme (Ibrexafungerp) at any time during pregnancy or whose conception is estimated to have occurred within four days after receiving the last dose of Brexafemme. |
This is not an interventional study |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Major Structural Defects
Tidsramme: From Brexafemme exposure up to one year after birth
|
To collect and describe selected fetal/neonatal/infant outcomes (i.e., major and minor congenital malformations, small for gestational age, and postnatal growth and development) at birth and through up to the first year of life of infants born to women exposed to ibrexafungerp during the defined pregnancy exposure window |
From Brexafemme exposure up to one year after birth
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
To collect and describe pregnancy outcomes
Tidsramme: From Brexafemme exposure up to one year post birth
|
Live birth, spontaneous abortions, stillbirths, elective abortions, and preterm births |
From Brexafemme exposure up to one year post birth
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Kjønnssykdommer
- Munnsykdommer
- Stomatognatiske sykdommer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Infeksjoner
- Kjønnssykdommer, kvinner
- Bakterielle infeksjoner og mykoser
- Vulva sykdommer
- Vulvitt
- Vaginitt
- Mykoser
- Vaginale sykdommer
- Candidiasis
- Candidiasis, vulvovaginal
- Vulvovaginitt
- Candidiasis, oral
Andre studie-ID-numre
- 222030
- SCY-078-401 (Annen identifikator: Scynexis)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .